FiercePharmaAsia—Sun’s gloomy outlook, Grail’s Asian M&A, InventisBio’s $19M series B
admin 2nd June 2017 Uncategorised 0Sun’s U.S. sales dropped 34% last quarter to $381 million, Illumina spinoff Grail is tapping into the Asian market by merging with Hong Kong-based Cirina, and Shanghai-based cancer and gout biotech InventisBio has raised $19 million in a series B financing.
More: FiercePharmaAsia—Sun’s gloomy outlook, Grail’s Asian M&A, InventisBio’s M series B
Source: fierce